Gabapentin Tablets — Class III drug recall D-0570-2023
Terminated recall by The Harvard Drug Group, reported 2023-05-17, distributed nationwide. Product mixup: one foreign tablet found in product.
| Recall number | D-0570-2023 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | The Harvard Drug Group, La Vergne, TN, United States |
| Recall initiated | 2023-04-24 |
| Classified | 2023-05-10 |
| Reported by FDA | 2023-05-17 |
| Terminated | 2024-04-30 |
| Distributed | Nationwide (US) |
| Quantity | 3,984 cartons |
| NDC | 00904-6823, 00904-6823-61, 00904-7108, 00904-7108-61 |
| Lot numbers | T04468 |
| Expiration dates | 2024-10 |
Product
Gabapentin Tablets, USP 600 mg, packaged in Cartons of 100 tablets (10 tablets per blister pack x 10), Rx Only, Distributed by: Aurobindo Pharma USA, Inc. East Windsor, NJ 08520 Distributed by: Major Pharmaceuticals 17177 N Laurel Park Dr., Suite 233 Livonia, MI 48152 USA, NDC 0904-6823-61
Reason for recall
Product mixup: one foreign tablet found in product.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0570-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.